[4'-epidoxorubicin: its cardiotoxicity. Possible cardiac protection with gallopamil, a drug with calcium-antagonist action].
The 4'-EPI-doxorubicin (4'-EDX) has shown antitumoral activity against a broad spectrum of human tumors. The same clinical reports have shown therapeutic activity comparable to doxorubicin (adriamycin), but a lower cardiac toxicity. 4'-EDX cardiotoxicity appears after highest cumulative doses: 935 mg/m2 bs for 4'-EDX vs 550 mg/m2 bs for adriamycin. Moreover we have observed a protective action of the calcium antagonist gallopamil. We have found an improvement in ventricular performance after using gallopamil, and a reduction of 4'-EDX cardiotoxicity. Cardiac function was evaluated by EKS, STI, echography, myocardial scintigraphy course. Our result indicates the possibility of treating tumors without serious cardiotoxic by 4'-EDX and gallopamil.
Polverino
W
W
Servizio di Cardiologia, Istituto Nazionale Tumori, Napoli.
Basso
A
A
Bonelli
A
A
Muto
P
P
Cittadini
A
A
Salvatore
M
M
D000328:Adult; D000368:Aged; D004452:Echocardiography; D004562:Electrocardiography; D015251:Epirubicin / Q000008:administration & dosage / Q000633:toxicity*; D005260:Female; D005711:Gallopamil / Q000008:administration & dosage / Q000494:pharmacology*; D006321:Heart / Q000000981:diagnostic imaging / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D011877:Radionuclide Imaging; D013997:Time Factors
D005711:Gallopamil; D015251:Epirubicin
La 4'-epidoxorubicina: sua cardiotossicità. Eventuale cardioprotezione con il gallopamil, farmaco ad azione calcioantagonista.